Verrusio W, Andreozzi P, Summa M L, Marigliano V, Gueli N, Cacciafesta M
W.Verrusio, M.D. Ph. D. st.
J Nutr Health Aging. 2014 Apr;18(4):449-50. doi: 10.1007/s12603-014-0027-1.
the possible therapeutic role of vitamin D in different kind of diseases explains the growing interest in this vitamin due to its pleiotropic effects. This short report shows preliminary results of prevalence of hypovitaminosis D in a group of patients and proposes a oral supplement therapy effective in correcting hypovitaminosis in a short time, without side effects.
243 patients (aged 26-93; 67 males) were enrolled at this study. We evaluated plasma levels of 25-hydroxyvitamin D [25(OH)D] with the following cut-off values: <10 ng/ml or <0-25 nmol/L (deficient), 10-30 ng/ml or 25-75 nmol/L 30-50 (insufficient) and > 30 ng/ml or > 50 nmol/L (normal). The first 73 patients with hypovitaminosis D received at baseline 25,000 IU (Cholecalciferol) per os twice a month (Tp.A). The next patients (Tp.B) at baseline received a loading dose of 50,000 IU once a week for 8 weeks, followed by a maintenance dose of 25,000 IU twice a month.
hypovitaminosis D is a widespread condition (i.e., 82.3%) not only in elderly (75.6% of 75 patients aged <65 yrs and 86.5% of 168 subjects aged >65 yrs). Preliminary results at 6 months show that Tp.B is more effective in correcting hypovitaminosis D (baseline 14.4 ± 5.3 ng/ml; 24 wk 43.3 ± 14.7 ng/ml; p<0.0001).
hypovitaminosis D is an important public health problem. We believe it is important to quickly achieve normal Vit. D plasma values in order to produce pleiotropic effects.
维生素D在不同疾病中可能的治疗作用，因其多效性作用引发了人们对这种维生素越来越浓厚的兴趣。本简短报告展示了一组患者中维生素D缺乏症的初步流行情况，并提出了一种能在短时间内有效纠正维生素D缺乏且无副作用的口服补充疗法。
本研究纳入了243名患者（年龄26 - 93岁；男性67名）。我们评估了血浆25 - 羟基维生素D [25(OH)D]水平，其临界值如下：<10 ng/ml或<25 nmol/L（缺乏），10 - 30 ng/ml或25 - 75 nmol/L（不足），>30 ng/ml或>50 nmol/L（正常）。最初73名维生素D缺乏症患者在基线时每月口服两次25,000 IU（胆钙化醇）（Tp.A组）。接下来的患者（Tp.B组）在基线时每周接受一次50,000 IU的负荷剂量，持续8周，随后每月口服两次25,000 IU的维持剂量。
维生素D缺乏症是一种普遍存在的情况（即82.3%），不仅在老年人中如此（65岁以下的75名患者中占75.6%，65岁以上的168名受试者中占86.5%）。6个月时的初步结果表明，Tp.B组在纠正维生素D缺乏方面更有效（基线时14.4 ± 5.3 ng/ml；24周时43.3 ± 14.7 ng/ml；p<0.0001）。
维生素D缺乏症是一个重要的公共卫生问题。我们认为迅速使维生素D血浆值达到正常水平以产生多效性作用非常重要。
